These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1474169)

  • 1. Classifying antiarrhythmic actions: by facts or speculation.
    Vaughan Williams EM
    J Clin Pharmacol; 1992 Nov; 32(11):964-77. PubMed ID: 1474169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial.
    Vaughan Williams EM
    J Clin Pharmacol; 1991 Feb; 31(2):123-35. PubMed ID: 1901320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Circulation; 1991 Oct; 84(4):1831-51. PubMed ID: 1717173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Class-I antiarrhythmic drugs].
    Kuga K; Sugishita Y
    Nihon Rinsho; 1996 Aug; 54(8):2110-6. PubMed ID: 8810785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can antiarrhythmic agents be selected based on mechanism of action?
    Lau W; Newman D; Dorian P
    Drugs; 2000 Dec; 60(6):1315-28. PubMed ID: 11152014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 'Sicilian Gambit'. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Eur Heart J; 1991 Oct; 12(10):1112-31. PubMed ID: 1723682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crime, misdemeanor, and arrhythmia decoding CAST.
    Kerin NZ
    J Clin Pharmacol; 1991 Nov; 31(11):1044-52. PubMed ID: 1753008
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of ventricular arrhythmias after CAST.
    Tonkin AM
    Med J Aust; 1992 Apr; 156(7):488-92. PubMed ID: 1372950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antiarrhythmic drugs.
    Nestico PF; Morganroth J; Horowitz LN
    Drugs; 1988 Mar; 35(3):286-319. PubMed ID: 3286214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
    Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
    Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology).
    Kodama I; Ogawa S; Inoue H; Kasanuki H; Kato T; Mitamura H; Hiraoka M; Sugimoto T
    Jpn Circ J; 1999 Jan; 63(1):1-12. PubMed ID: 10084381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spectrum of CAST I and II.
    Somberg J
    J Clin Pharmacol; 1991 Nov; 31(11):1041. PubMed ID: 1721629
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy with investigational antiarrhythmic drugs.
    Mead RH; Harrison DC
    Med Clin North Am; 1984 Sep; 68(5):1321-37. PubMed ID: 6436596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial.
    Anderson JL
    J Clin Pharmacol; 1990 Nov; 30(11):981-9. PubMed ID: 2122984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sicilian Gambit and antiarrhythmic drug development.
    Colatsky TJ
    Cardiovasc Res; 1992 Jun; 26(6):562-5. PubMed ID: 1333361
    [No Abstract]   [Full Text] [Related]  

  • 16. The cardiac arrhythmia suppression trial: implications for antiarrhythmic drug development.
    Pratt CM; Moye L
    J Clin Pharmacol; 1990 Nov; 30(11):967-74. PubMed ID: 2122983
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.
    Akiyama T; Pawitan Y; Campbell WB; Papa L; Barker AH; Rubbert P; Friedman L; Keller M; Josephson RA
    J Am Geriatr Soc; 1992 Jul; 40(7):666-72. PubMed ID: 1607582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What is the latest in anti-arrhythmia therapy?].
    Gloor HO
    Schweiz Med Wochenschr; 1991 Nov; 121(47):1711-4. PubMed ID: 1720259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.
    Harron DW; Brogden RN; Faulds D; Fitton A
    Drugs; 1992 May; 43(5):734-59. PubMed ID: 1379150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.